M
Mario Boccadoro
Researcher at University of Turin
Publications - 670
Citations - 39049
Mario Boccadoro is an academic researcher from University of Turin. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 83, co-authored 638 publications receiving 34589 citations. Previous affiliations of Mario Boccadoro include Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
Michele Cavo,Meral Beksac,Lucia Pantani,Maria Teresa Petrucci,Meletios A. Dimopoulos,Luca Dozza,Bronno van der Holt,Sonja Zweegman,Stefania Oliva,Vincent H.J. van der Velden,Elena Zamagni,Giuseppe A. Palumbo,Francesca Patriarca,Vittorio Montefusco,Monica Galli,Vladimir Maisnar,Barbara Gamberi,Markus Hansson,Angelo Belotti,Ludek Pour,Paula F. Ypma,Mariella Grasso,Alexsandra Croockewit,Stelvio Ballanti,Massimo Offidani,Iolanda Vincelli,Renato Zambello,Anna Marina Liberati,Niels Frost Andersen,Annemiek Broijl,Rossella Troia,Anna Pascarella,Giulia Benevolo,Mark-David Levin,Gerard M. J. Bos,Heinz Ludwig,Sara Aquino,Anna Maria Morelli,Ka Lung Wu,Rinske Boersma,Roman Hájek,Marc Durian,Peter A. von dem Borne,Tommaso Caravita di Toritto,Thilo Zander,Christoph Driessen,Giorgina Specchia,Anders Waage,Peter Gimsing,Ulf-Henrik Mellqvist,Marinus van Marwijk Kooy,Monique C. Minnema,Caroline Mandigers,Anna Maria Cafro,Angelo D. Palmas,Susanna Carvalho,Andrew Spencer,Mario Boccadoro,Pieter Sonneveld +58 more
TL;DR: Progressive progression-free survival was significantly improved with autologous HSCT compared with VMP and bortezomib-melphalan-prednisone (VMP) as intensification therapy, and bORTezomIB-lenalidomide-dexamethasone (VRD) consolidation therapy with no consolidation.
Journal ArticleDOI
Early CPAP prevents evolution of acute lung injury in patients with hematologic malignancy
Vincenzo Squadrone,Massimo Massaia,Benedetto Bruno,Filippo Marmont,Michele Falda,Carlotta Bagna,Stefania Bertone,Claudia Filippini,Arthur S. Slutsky,Umberto Vitolo,Mario Boccadoro,V. Marco Ranieri +11 more
TL;DR: This study suggests that early use of CPAP on the hematological ward in patients with early changes in respiratory variables prevents evolution to acute lung injury requiring mechanical ventilation and ICU admission.
Journal ArticleDOI
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation
Antonio Palumbo,Orhan Sezer,Robert A. Kyle,Jesús F. San Miguel,Robert Z. Orlowski,Philippe Moreau,Ruben Niesvizky,Gareth J. Morgan,Raymond L. Comenzo,Pieter Sonneveld,Shaji Kumar,Roman Hájek,Sergio Giralt,Sara Bringhen,Kenneth C. Anderson,Kenneth C. Anderson,Paul G. Richardson,Michele Cavo,Faith E. Davies,Joan Bladé,Hermann Einsele,Meletios A. Dimopoulos,Andrew Spencer,Angela Dispenzieri,Tony Reiman,K. Shimizu,Je-Hwan Lee,Michel Attal,Mario Boccadoro,M.V. Mateos,Wei Chen,Heinz Ludwig,Douglas E. Joshua,James Chim,V. Hungria,Ingemar Turesson,Brian G.M. Durie,Sagar Lonial +37 more
TL;DR: Recommendations on the diagnosis, treatment of newly diagnosed non-transplant-eligible patients and the management of complications occurring during induction therapy among these patients will aid the physician in daily clinical practice and ensure optimal care for patients with MM.
Journal ArticleDOI
Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates
Vittorio Montefusco,Francesco Spina,Rosalba Miceli,Massimo Maniezzo,Maria Teresa Ambrosini,Lucia Farina,Sheila Piva,Antonio Palumbo,Mario Boccadoro,Paolo Corradini +9 more
TL;DR: It is speculated that antibiotic prophylaxis before dental procedures may prevent ONJ occurrence after dental procedures, which had a protective effect.
Journal ArticleDOI
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.
Sonia Vallet,Noopur Raje,Kenji Ishitsuka,Teru Hideshima,Klaus Podar,Shweta Chhetri,Samantha Pozzi,Iris Breitkreutz,Tanyel Kiziltepe,Hiroshi Yasui,Enrique M. Ocio,Norihiko Shiraishi,Janice Jin,Yutaka Okawa,Hiroshi Ikeda,Siddhartha Mukherjee,Nileshwari Vaghela,Diana Cirstea,Marco Ladetto,Mario Boccadoro,Kenneth C. Anderson +20 more
TL;DR: Novel biologic sequelae of CCL3 and its inhibition in both osteoclastogenesis and MM cell growth are shown, providing the preclinical rationale for clinical trials of MLN3897 to treat OBD in MM.